Abstract 168P
Background
It is important to predict prognosis in patients with advanced gastric cancer receiving chemotherapy. Several studies have reported that Glasgow prognostic score (GPS), which was based on serum albumin (Alb) and C-reactive protein (CRP), was associated with poor prognosis in many cancers. However, it is unclear whether GPS has prognostic value when patients receive Irinotecan, which is a key drug of advanced gastric cancer.
Methods
We conducted a retrospective multicenter study and investigated association between efficacy and GPS in patients who received irinotecan monotherapy between January 2010 and December 2017. All patients had to receive fluoropyrimidine and platinum as prior therapy. GPS was identified that GPS 0 was CRP ≤1.0 mg/dL and Alb ≥3.5 g/dL, GPS 1 was CRP >1.0 mg/dL or Alb <3.5 g/dL, and GPS 2 was CRP >1.0 mg/dL and Alb <3.5 g/dL.
Results
There were 174 patients at 8 centers included in this study. The number of patients with GPS 0/1/2 was 76/56/42, respectively. In GPS 0/1/2 patients, performance status (0-1/2≤), treatment line 2nd/3rd or later, and HER2 status were significantly different among them(p < 0.01). As for safety, there was no significant difference among GPS 0/1/2 patients. In GPS 0/1/2 patients, median PFS were 3.7/2.8/2.0 months (p < 0.01), median OS were 11.9/7.2/6.7 months (p < 0.01), respectively. In multivariate analysis, GPS was associated with shorter PFS (GPS 0 vs 1/0vs 2 : HR 1.180/2.378, 95%C.I. 0.793-1.758/1.405-4.024, p = 0.414/0.001), and shorter OS (GPS 0 vs 1/0vs 2 : HR 1.520/2.529, 95%C.I. 1.002-2.305/1.518-4.213, p = 0.049/<0.001).
Conclusions
In this analysis, GPS might be a predictive and prognostic factor in treatment with irinotecan monotherapy for patients with AGC.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Yoshito Komatsu.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
175P - Hypermethylation of the PCDHB15 promoter predicts the prognosis in gastric cancer
Presenter: Yu-ting Lee
Session: Poster display session
Resources:
Abstract
176P - DCLK1 promotes tumour invasion and metastasis through epithelial-mesenchymal transition and the MEK/ERK pathway in esophageal squamous cell carcinoma
Presenter: Jiannan Yao
Session: Poster display session
Resources:
Abstract
177P - Comparison of nab-paclitaxel plus ramcirumab and paclitaxel plus ramcirumab in patients with pretreated metastatic gastric cancer
Presenter: Yosuke Horita
Session: Poster display session
Resources:
Abstract
178P - Chief cell in stomach have stem cell activity and potential to develop gastric cancer
Presenter: Akihiro Yamamura
Session: Poster display session
Resources:
Abstract
179P - Postoperative Adjuvant transarterial chemoembolization versus surgery alone for resected hepatocellular carcinoma: A propensity-score matching study
Presenter: Mingyu Chen
Session: Poster display session
Resources:
Abstract
180P - LHPP inhibit the cell proliferation and EMT via the TGFβ/SMAD3 signaling pathway in iCCA
Presenter: Dan Wang
Session: Poster display session
Resources:
Abstract
181P - The emerging role of third-line gemcitabine plus nab-paclitaxel in advanced pancreatic adenocarcinoma
Presenter: Andrew Dean
Session: Poster display session
Resources:
Abstract
182P - Durable response to second-line m-FOLFIRINOX for advanced pancreatic adenocarcinoma in patients with performance status of two or less
Presenter: Adarsh Das
Session: Poster display session
Resources:
Abstract
183P - Epidemiologic profile of gastric cancer in East Azerbaijan, Iran: 2 years population-based cancer registry results
Presenter: Pooneh Jabbaripour
Session: Poster display session
Resources:
Abstract
184P - Expression pattern of CDK12 protein in gastric cancer and its positive correlation with CD8+ cell density and CCL12 expression
Presenter: Jun Ji
Session: Poster display session
Resources:
Abstract